We’re on the ground at AAD 2026! Visit booth #4155 to connect with our team and explore progress in EPP research. And don’t miss our disease state education theater on March 27th at 11:15am in Theater 2.
English
Disc Medicine
153 posts
Disc Medicine
@DiscMedicine
Disc Medicine is applying new insights in heme biosynthesis and iron metabolism to develop first-in-class therapies for #hematologic diseases.
Cambridge, MA Katılım Ekim 2019
61 Takip Edilen294 Takipçiler
We’re thrilled to share that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Thank you to the patients, families, investigators, and study teams who made this milestone possible. Read more: globenewswire.com/news-release/2…
English
Disc is heading to the 2026 AAD Annual Meeting next week! Visit booth #4155 to learn the latest on bitopertin for EPP and connect with our team. We can’t wait to engage with the dermatology community!
English
On Rare Disease Day, we remember the people and families behind every diagnosis. At Disc, we’re committed to advancing therapies for rare hematologic diseases and delivering impact to patients.
Learn more at rarediseaseday.org and explore Disc at discmedicine.com
English
Today we reported our fourth quarter and full-year 2025 financial results and shared recent program and corporate updates. Read more about our progress in bitopertin, DISC-0974, and DISC-3405 in the latest press release: ir.discmedicine.com/news-releases/…
English
We’re pleased to welcome Lisa Amaya Price as our Chief HR Officer! With 25+ years of experience in HR and organizational leadership, Lisa will play a critical role as we advance our mission to develop new medicines for blood-based diseases. Learn more: ir.discmedicine.com/news-releases/…
English
2025 was a year of strong momentum across our #Hematology portfolio. In 2026, we’re advancing our clinical programs with a clear focus on delivering meaningful progress for patients: ir.discmedicine.com/news-releases/…
#EPP #XLP #Anemia #Myelofibrosis #PolycythemiaVera #SickleCellDisease
English
Great #ASH25 recap featuring CEO, John Quisel, with @BiotechTV, discussing positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in #Anemia of #Myelofibrosis.
DISC-0974 is an investigational agent and not approved for use as a therapy in any jurisdiction worldwide.
BiotechTV@BiotechTV
𝐀𝐒𝐇 𝟐𝟎𝟐𝟓: @DiscMedicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis. $IRON Full video: biotechtv.com/post/disc-medi…
English
Today at the @ASH_hematology Annual Meeting, we shared a first look at positive data from our Phase 2 RALLY-MF trial of DISC-0974 in #Anemia of #Myelofibrosis, as well as a trial design poster for DISC-3405 in #PolycythemiaVera. Read more: ir.discmedicine.com/news-releases/…
English
We reported our Q3 financial results and operational progress. A key highlight is receiving the FDA CNPV, designed to shorten the NDA review process of #Bitopertin in #EPP to 1-2 months. Read more about other progress in our pipeline: ir.discmedicine.com/news-releases/…
English
Disc will share two poster presentations on initial data from the RALLY-MF Ph 2 trial of DISC-0974 in #Anemia of #MF and the design of our ongoing Ph 2 trial of DISC-3405 in #PV, at the @ASH_hematology Meeting in December. Read more: ir.discmedicine.com/news-releases/…
English
@BiotechTV recently featured CEO John Quisel in a segment on Disc’s receipt of a Commissioner’s National Priority Voucher from the U.S. FDA for #Bitopertin in #EPP, including #XLP. Watch the full video: biotechtv.com/post/disc-medi…
BiotechTV@BiotechTV
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: @DiscMedicine's CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV). Full video: biotechtv.com/post/disc-medi…
English
We are excited to announce we have received a Commissioner’s National Priority Voucher (CNPV) from the U.S. Food and Drug Administration for #Bitopertin in #ErythropoieticProtoporphyria (#EPP), including #XLinkedProtoporphyria (#XLP). Read more: ir.discmedicine.com/news-releases/…
English
We're excited to share the publication of new preclinical study with Boston Children's Hospital showing bitopertin’s potential to lower PPIX levels and prevent liver disease in #EPP. Thank you to the team for advancing this important science: jci.org/articles/view/…
Journal of Clinical Investigation@jclinicalinvest
Erythropoietic protoporphyria causes phototoxicity and can also involve the liver due to the accumulation of protoporphyrin IX in red blood cells. Mark D. Fleming & team @BostonChildrens now show bitopertin treatment reduces PPIX accumulation and mitigates liver disease in EPP models: jci.org/articles/view/…
English
We are excited to announce submission a New Drug Application to the U.S. FDA for #Bitopertin in #ErythropoieticProtoporphyria (#EPP) and #XLinkedProtoporphyria (#XLP) under the accelerated approval pathway. Read the full announcement here: ir.discmedicine.com/news-releases/…
English
Grateful to Patti and Dr. Raajit Rampal for sharing their perspectives in honor of #MPNAwarenessDay. Their insights shed light on #MyeloproliferativeNeoplasms like #PolycythemiaVera & #Myelofibrosis. Learn more about our approach at discmedicine.com
English
We reported our Q2 financial results and operational progress. A key highlight is being on track to submit NDA for #Bitopertin in #ErythropoieticProtoporphyria under accelerated approval pathway in October. Read more about other progress in our pipeline: ir.discmedicine.com/news-releases/…
English
#EPP & #XLP are more than light sensitivity — #PPIX buildup can also affect liver & bone health, as well as quality of life.
Our new sites offer dedicated resources for HCPs and people living with EPP. Start exploring at PPIXiswhyhcp.com and PPIXiswhy.com
English
Disc is thrilled to share positive clinical data across our portfolio at the @EHA_Hematology Annual Congress. Read more about our collection of data from 5 posters and register for our corporate call on Monday, June 16 at 8am EST / 2pm CEST here: ir.discmedicine.com/news-releases/…
English
Grateful to Drs. Amy Dickey and Rebecca Karp for joining our team for a special Lunch & Learn in honor of #GlobalPorphyriaDay, which is May 18. They shared valuable insights that deepen our understanding of #EPP, #XLP, and the broader challenges facing the #Porphyria community.
English